Materials and methods for the treatment of gastroesophageal reflux disease
    3.
    再颁专利
    Materials and methods for the treatment of gastroesophageal reflux disease 有权
    用于治疗胃食管反流病的材料和方法

    公开(公告)号:USRE42412E1

    公开(公告)日:2011-05-31

    申请号:US11962592

    申请日:2007-12-21

    IPC分类号: A61K31/445 C07D211/56

    摘要: The subject invention provides novel compounds and compositions for the safe and effective treatment of gastroesophageal reflux and related conditions. In a preferred embodiment, the compositions of the subject invention comprise esterified cisapride derivatives. These compositions possess potent activity in treating gastroesophageal reflux disease and substantially reduce adverse effects associated with the administration of cisapride. These adverse effects include, but are not limited to, diarrhea, abdominal cramping and elevations of blood pressure and heart rate.

    摘要翻译: 本发明提供了用于安全有效地治疗胃食管反流和相关病症的新型化合物和组合物。 在优选的实施方案中,本发明的组合物包含酯化的西沙必利衍生物。 这些组合物在治疗胃食管反流疾病中具有有效的活性,并且显着减少与西沙必利施用相关的不良反应。 这些不良影响包括但不限于腹泻,腹部绞痛和血压升高和心率升高。

    Dibenzo[b,f][1,4]oxazapine compounds
    8.
    发明授权
    Dibenzo[b,f][1,4]oxazapine compounds 有权
    二苯并[b,f] [1,4]恶唑氮化合物

    公开(公告)号:US08093237B2

    公开(公告)日:2012-01-10

    申请号:US12047858

    申请日:2008-03-13

    摘要: The present invention relates to 11-(piperazin-1-yl)dibenzo[b,f][1,4 ]oxazapine compounds of the formula: where the variables are as defined herein, their salts and pharmaceutically acceptable compositions thereof. Methods of preparing these compounds are also described. These compounds may be used in the treatment of disorders such as schizophrenia, treatment resistant schizophrenia, bipolar disorder, psychotic depression, treatment resistant depression, schizophrenia-associated depression, treatment resistant OCD, autism, senile psychosis, psychotic dementia, L-DOPA induced psychosis, psychogenic polydipsia, psychotic symptoms of neurological disorders, sleep disorders.

    摘要翻译: 本发明涉及下式的11-(哌嗪-1-基)二苯并[b,f] [1,4]恶唑氮化合物:其中变量如本文所定义,其盐和药学上可接受的组合物。 还描述了制备这些化合物的方法。 这些化合物可用于治疗精神分裂症,治疗耐药性精神分裂症,双相性精神障碍,精神病抑郁症,治疗耐药性抑郁症,精神分裂症相关抑郁症,治疗耐药性OCD,孤独症,老年性精神病,精神病性痴呆,L-DOPA诱发的精神病 ,心理性多饮,精神病性神经障碍症状,睡眠障碍。

    Materials and methods for treating coagulation disorders
    9.
    发明申请
    Materials and methods for treating coagulation disorders 有权
    用于治疗凝血障碍的材料和方法

    公开(公告)号:US20050245603A1

    公开(公告)日:2005-11-03

    申请号:US11101714

    申请日:2005-04-08

    CPC分类号: C07D311/56

    摘要: The subject invention provides anticoagulant compounds of formula I: and pharmaceutically acceptable salts thereof, wherein R1, R3, n and Ar are as defined herein. The compounds of the subject invention can be used to treat at-risk populations thereby bringing relief of symptoms, improving the quality of life, preventing acute and long-term complications, reducing mortality and treating accompanying disorders. The invention further comprises pharmaceutical compositions comprising the compounds and salts of the invention, as well as methods of using the compounds, salts, and compositions of the invention.

    摘要翻译: 本发明提供式I的抗凝血剂化合物及其药学上可接受的盐,其中R 1,R 3,n和Ar如本文所定义。 本发明的化合物可用于治疗危险人群,从而缓解症状,改善生活质量,预防急性和长期并发症,降低死亡率和治疗伴随的疾病。 本发明还包括包含本发明化合物和盐的药物组合物,以及使用本发明化合物,盐和组合物的方法。